The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
But acquisition charges drag earnings into loss
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Subscribe To Our Newsletter & Stay Updated
